Pharmacokinetic Drug-Drug Interaction Study Between Raltegravir and Atorvastatin 20 mg in Healthy Volunteers

被引:10
|
作者
Blonk, Maren [1 ]
van Beek, Michiel [2 ]
Colbers, Angela [1 ]
Schouwenberg, Bas [2 ]
Burger, David [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Pharm, NL-6525 GA Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Pharmacol & Toxicol, NL-6525 GA Nijmegen, Netherlands
关键词
drug-drug interaction; pharmacokinetics; HIV; hyper-cholesterolemia; raltegravir; atorvastatin; HIV-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; PROTEASE INHIBITORS; STATINS; DYSLIPIDEMIA; ROSUVASTATIN; VARIABILITY; ACTIVATION; TOXICITY; LACTONE;
D O I
10.1097/QAI.0000000000000544
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Dyslipidemia is highly prevalent among patients with HIV infection and contributes to an increased risk of cardiovascular disease. We investigated the influence of a frequently used statin, atorvastatin, on the pharmacokinetics of the HIV-integrase inhibitor raltegravir and vice versa. Methods: Open-label, crossover 3-period phase I trial in 24 healthy volunteers. Subjects took raltegravir 400 mg two times a day for 7 days, atorvastatin 20 mg once a day for 7 days, and the combination of atorvastatin 20 mg once a day + raltegravir 400 mg two times a day for 7 days with 2-week washout periods in between. Intensive steady-state 12- and 24-hour pharmacokinetic blood sampling was performed. Geometric mean ratios of the test treatment (combination raltegravir + atorvastatin) versus the reference treatment (raltegravir or atorvastatin alone) and 90% confidence intervals were calculated for the area under the plasma concentration-time curve (AUC). Fasting lipid profiles were obtained to assess short-term lipid-lowering effect of atorvastatin with or without concomitant raltegravir use. Results: Twenty-four healthy volunteers (11 males) were enrolled. All but 1 subject completed the trial, and no serious adverse events were reported. Geometric mean ratios (90% confidence interval) were 1.01 (0.68-1.51) for raltegravir AUC(0) (12h) and 1.00 (0.90-1.11) for atorvastatin AUC(0) (24h). The AUC(0) (24h) metabolite-to-parent ratio for atorvastatin lactone, ortho-hydroxy, and para-hydroxy atorvastatin did not change during concomitant raltegravir use. The effect of atorvastatin on low-density lipoprotein cholesterol was not significantly different when combined with raltegravir versus atorvastatin alone (P = 0.638). Conclusions: Atorvastatin 20 mg has no clinically relevant effect on the pharmacokinetics of raltegravir and vice versa. The combination was well tolerated and can be administered without dose adjustments.
引用
收藏
页码:44 / 51
页数:8
相关论文
共 50 条
  • [1] Pharmacokinetic drug-drug interaction study between raltegravir and citalopram
    Blonk, Maren I.
    Langemeijer, Charlotte C. A.
    Colbers, Angela P. H.
    Hoogtanders, Karin E. J.
    van Schaik, Ron H. N.
    Schouwenberg, Bas J. J. W.
    [J]. ANTIVIRAL THERAPY, 2016, 21 (02) : 143 - 152
  • [2] A pharmacokinetic drug-drug interaction study between pregabalin and tramadol in healthy volunteers
    Soyoung Lee
    Yun Kim
    Janice Ji Sung Lee
    Guangjin Im
    Joo-Youn Cho
    Jae-Yong Chung
    Seonghae Yoon
    [J]. European Journal of Clinical Pharmacology, 2018, 74 : 1605 - 1613
  • [3] A pharmacokinetic drug-drug interaction study between pregabalin and tramadol in healthy volunteers
    Lee, Soyoung
    Kim, Yun
    Lee, Janice Ji Sung
    Im, Guangjin
    Cho, Joo-Youn
    Chung, Jae-Yong
    Yoon, Seonghae
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (12) : 1605 - 1613
  • [4] Drug-Drug Interactions Between Raltegravir and Pravastatin in Healthy Volunteers
    van Luin, Matthijs
    Colbers, Angela
    Kolmer, Eleonora W. J. van Ewijk-Beneken
    Verweij-van Wissen, Corrien P. W. G. M.
    Schouwenberg, Bas
    Hoitsma, Arjen
    da Silva, Hugo G.
    Burger, David M.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (01) : 82 - 86
  • [5] Evaluation of the Pharmacokinetic Drug-Drug Interaction between Micronized Fenofibrate and Pitavastatin in Healthy Volunteers
    Lee, Hae Won
    Kang, Woo Youl
    Jung, Wookjae
    Gwon, Mi-Ri
    Cho, Kyunghee
    Yang, Dong Heon
    Yoon, Young-Ran
    Seong, Sook Jin
    [J]. PHARMACEUTICS, 2020, 12 (09) : 1 - 10
  • [6] Pharmacokinetic drug-drug interaction analysis of pyramax® and ritonavir in healthy volunteers
    Duparc, S.
    Borghini-Fuhrer, I.
    Fleckenstein, L.
    Jung, D.
    Lopez-Lazaro, L.
    Methaneethorn, J.
    Morris, C.
    Pokorny, R.
    Shin, C. -S.
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2011, 16 : 138 - 138
  • [7] Pharmacokinetic drug-drug interaction study of benznidazole and E1224 in healthy male volunteers
    Ribeiro, I.
    Feleder, E.
    Halabe, K.
    Yerino, G.
    Otero, A.
    Blum, B.
    Fernandes, J.
    Barreira, F.
    Duncanson, F.
    Everson, M.
    Schuck, E.
    Garcia-Bounissen, F.
    Bedor, D.
    Evene, E.
    Gualano, V.
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2015, 20 : 328 - 328
  • [8] In vitro study of the drug-drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers
    Lu, Jinmiao
    Tian, Xusheng
    Tang, Dong
    Zhou, Xinyi
    Xu, Zengyan
    Ding, Juping
    Wang, Tong
    Yu, Qiang
    Ding, Jinsong
    [J]. XENOBIOTICA, 2021, 51 (10) : 1122 - 1131
  • [9] Drug-Drug Interaction of Letermovir and Atorvastatin in Healthy Participants
    McCrea, Jacqueline B.
    Menzel, Karsten
    Adedoyin, Adedayo
    Cho, Carolyn R.
    Fox-Bosetti, Sabrina
    Macha, Sreeraj
    Zhao, Tian
    Liu, Fang
    Panebianco, Deborah
    Stoch, S. Aubrey
    Iwamoto, Marian
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (04): : 420 - 428
  • [10] Is There a Drug-Drug Interaction Between Darunavir/Ritonavir and Raltegravir?
    Fabbiani, Massimiliano
    Navarra, Pierluigi
    Cauda, Roberto
    De Luca, Andrea
    Di Giambenedetto, Simona
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 60 (01) : E18 - E20